Triastek, Inc. and Siemens Ltd., China have signed a strategic collaboration agreement to provide digital technologies for the global pharmaceutical industry. Combining Triastek's industry-leading 3D printing and digital pharmaceutical technologies and Siemens' global leadership in automation and digitization is expected to lead to innovative and transformative solutions for the development and manufacturing of pharmaceuticals.
Regulatory agencies including the U.S. FDA (Food and Drug Administration), European EMA (European Medicines Agency), and China's NMPA (National Medical Products Administration) have encouraged pharmaceutical companies to modernize their manufacturing processes through adopting continuous manufacturing processes and digital technologies. Triastek is actively implementing the continuous manufacturing approach in conjunction with advanced digital tools to streamline and improve their manufacturing processes and products. Combining these innovations with Siemens' digitization and automation expertise will address regulatory agency desires to reduce pharmaceutical product quality issues, lower manufacturing costs, and improve availability of quality medicines to patients.
This collaboration between Triastek and Siemens will leverage their respective technological advantages, strengths, and capabilities to address pharmaceutical industry needs and improve patient outcomes. Triastek's proprietary pharmaceutical MED® (Melt Extrusion Deposition) 3D printing platform technology for R&D and mass production integrated with the advanced automation and digital technologies provided by Siemens will accelerate product R&D, and facilitate continuous manufacturing approaches, paperless production, real time product release, equipment and facility maintenance. These innovations are expected to improve production line throughput whilst maintaining the highest product quality.
Finally, in collaboration with Siemens, Triastek plans to establish an intelligent pharmaceutical manufacturing center, where a virtual laboratory, smart factory, and digital twin technologies will be incorporated into every aspect of pharmaceutical operations.